BR112022020956A8 - Análogos de peptídeo tirosina tirosina (pyy) de ação prolongada e métodos de uso - Google Patents
Análogos de peptídeo tirosina tirosina (pyy) de ação prolongada e métodos de usoInfo
- Publication number
- BR112022020956A8 BR112022020956A8 BR112022020956A BR112022020956A BR112022020956A8 BR 112022020956 A8 BR112022020956 A8 BR 112022020956A8 BR 112022020956 A BR112022020956 A BR 112022020956A BR 112022020956 A BR112022020956 A BR 112022020956A BR 112022020956 A8 BR112022020956 A8 BR 112022020956A8
- Authority
- BR
- Brazil
- Prior art keywords
- pyy
- methods
- polypeptides
- tyrosine
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invenção se refere a polipeptídeos isolados que são análogos de ação prolongada de PYY humana. Os polipeptídeos análogos de PYY divulgados têm propriedades físicoquímicas benéficas em relação a PYY endógena e polipeptídeos análogos de PYY sintéticos conhecidos, tal como meias-vidas de eliminação mais longas (isto é, ação prolongada) (t1/2) e solubilidade e estabilidade térmica melhoradas. Esta invenção também se refere a métodos de utilização de polipeptídeos análogos de PYY presentemente divulgados numa variedade de indicações terapêuticas, bem como a métodos de produção dos mesmos. Os polipeptídeos análogos de PYY divulgados são particularmente úteis em métodos de tratamento de doenças ou distúrbios metabólicos, tais como diabetes tipo 2, tratamento de obesidade e fornecimento de perda de peso e em métodos de tratamento de doença do fígado gordo não alcoólica (NAFLD) e/ou esteato-hepatite não alcoólica (NASH).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011649P | 2020-04-17 | 2020-04-17 | |
| US202063076459P | 2020-09-10 | 2020-09-10 | |
| PCT/US2021/027759 WO2021212023A1 (en) | 2020-04-17 | 2021-04-16 | Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112022020956A2 BR112022020956A2 (pt) | 2022-12-20 |
| BR112022020956A8 true BR112022020956A8 (pt) | 2023-01-10 |
Family
ID=76181192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020956A BR112022020956A8 (pt) | 2020-04-17 | 2021-04-16 | Análogos de peptídeo tirosina tirosina (pyy) de ação prolongada e métodos de uso |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11739134B2 (pt) |
| EP (1) | EP4136102A1 (pt) |
| JP (1) | JP2023522081A (pt) |
| KR (1) | KR20230039601A (pt) |
| CN (1) | CN115698053A (pt) |
| AU (1) | AU2021257477A1 (pt) |
| BR (1) | BR112022020956A8 (pt) |
| CA (1) | CA3175725A1 (pt) |
| IL (1) | IL297368A (pt) |
| MX (1) | MX2022013024A (pt) |
| TW (1) | TW202204390A (pt) |
| WO (1) | WO2021212023A1 (pt) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070027073A1 (en) * | 2003-04-08 | 2007-02-01 | Menachem Rubinstein | Long-acting derivatives of pyy agonists |
| CN101065133A (zh) | 2004-02-11 | 2007-10-31 | 安米林药品公司 | 胰多肽家族基序及含有这些基序的多肽 |
| AU2005316524B2 (en) * | 2004-12-13 | 2012-01-12 | Amylin Pharmaceuticals, Llc | Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same |
| GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| WO2014178018A1 (en) * | 2013-05-02 | 2014-11-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
| US20170137486A1 (en) | 2014-05-23 | 2017-05-18 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
| WO2015177573A1 (en) | 2014-05-23 | 2015-11-26 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
-
2021
- 2021-04-16 WO PCT/US2021/027759 patent/WO2021212023A1/en unknown
- 2021-04-16 KR KR1020227039816A patent/KR20230039601A/ko active Search and Examination
- 2021-04-16 IL IL297368A patent/IL297368A/en unknown
- 2021-04-16 JP JP2022563207A patent/JP2023522081A/ja active Pending
- 2021-04-16 CN CN202180042276.4A patent/CN115698053A/zh active Pending
- 2021-04-16 EP EP21728667.3A patent/EP4136102A1/en active Pending
- 2021-04-16 BR BR112022020956A patent/BR112022020956A8/pt unknown
- 2021-04-16 MX MX2022013024A patent/MX2022013024A/es unknown
- 2021-04-16 US US17/233,111 patent/US11739134B2/en active Active
- 2021-04-16 TW TW110113745A patent/TW202204390A/zh unknown
- 2021-04-16 CA CA3175725A patent/CA3175725A1/en active Pending
- 2021-04-16 AU AU2021257477A patent/AU2021257477A1/en active Pending
-
2023
- 2023-07-05 US US18/347,246 patent/US20240166708A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240166708A1 (en) | 2024-05-23 |
| BR112022020956A2 (pt) | 2022-12-20 |
| KR20230039601A (ko) | 2023-03-21 |
| US11739134B2 (en) | 2023-08-29 |
| AU2021257477A1 (en) | 2022-12-08 |
| US20220002371A1 (en) | 2022-01-06 |
| CN115698053A (zh) | 2023-02-03 |
| TW202204390A (zh) | 2022-02-01 |
| MX2022013024A (es) | 2023-03-15 |
| WO2021212023A1 (en) | 2021-10-21 |
| EP4136102A1 (en) | 2023-02-22 |
| JP2023522081A (ja) | 2023-05-26 |
| CA3175725A1 (en) | 2021-10-21 |
| IL297368A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018073511A2 (pt) | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos | |
| Baldo et al. | The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. | |
| KR102476550B1 (ko) | 선택적인 pyy 화합물 및 그것의 사용 | |
| US7723471B2 (en) | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same | |
| EP1824876B1 (en) | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same | |
| AR091866A1 (es) | Analogos del glucagon | |
| BRPI0411172A (pt) | peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica | |
| AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
| BRPI0610091A2 (pt) | anÁlogo de peptÍdeo 2 tipo glucagon (glp-2) ou um sal ou derivado farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um anÁlogo de glp-2, molÉcula de Ácido nucleico, vetor de expressço, cÉlula hospedeira, mÉtodo para a produÇço do anÁlogo de glp-2, uso de uma molÉcula de Ácido nucleico, um vetor de expressço ou uma cÉlula hospedeira, mÉtodos para tratamento de um distérbio relacionado ao estâmago e ao instestino em um paciente, para tratamento ou de prevenÇço de um efeito colateral de quimioterapia ou de terapia por radiaÇço a um paciente e para tratamento de distérbios neonatais, obesidade, osteoporose, ou condiÇÕes mediadas por dpp-iv, e, kit terapÊutico | |
| BRPI0313155B8 (pt) | composto químico derivado ou análogo de carotenóide, composição farmacêutica, e, uso do composto | |
| CL2022000178A1 (es) | Análogos de relaxina y métodos para usarlos | |
| JO3226B1 (ar) | مخفف توتر سطحي معاد التشكيل مطور يحتوي على نظائر بروتين مخفف للتوتر السطحي b(sp-b) وبروتين مخفف للتوتر السطحي c (sp-c) | |
| AR097701A1 (es) | Análogos de amilina | |
| CN105764919A (zh) | 在位置35具有β-高精氨酸置换的hPYY(1-36) | |
| MX2021004185A (es) | Polipeptidos analogos de la amilina humana y sus metodos de uso. | |
| BR112022020956A8 (pt) | Análogos de peptídeo tirosina tirosina (pyy) de ação prolongada e métodos de uso | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| JP4897970B2 (ja) | Ｍｓｈのアゴニストであるトリペプチド複合体 | |
| ATE503768T1 (de) | Synthetische lungensurfactant peptide | |
| BR112022020957A2 (pt) | Peptídeos seletivos a receptor de glucagon de ação prolongada e métodos de uso | |
| AR124395A1 (es) | Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos | |
| WO2017220706A1 (en) | Pharmaceutical compositions of fgf21 derivatives and uses thereof | |
| AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
| BR0309966A (pt) | Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos | |
| BR112023002525A2 (pt) | Análogos de ham15-52 e composição farmacêutica |